deferoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	792	70-51-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: deferoxamine deferoxamine mesylate deferoxamin desferrioxamine desferrioxamine mesilate deferoxamine mesilate desferrioxamine mesylate	Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Molecular weight: 560.69 Formula: C25H48N6O8 CLOGP: -0.18 LIPINSKI: 3 HAC: 14 HDO: 6 TPSA: 205.84 ALOGS: -3.75 ROTB: 23 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

deferoxamine
deferoxamine mesylate
deferoxamin
desferrioxamine
desferrioxamine mesilate
deferoxamine mesilate
desferrioxamine mesylate

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Molecular weight: 560.69
Formula: C25H48N6O8
CLOGP: -0.18
LIPINSKI: 3
HAC: 14
HDO: 6
TPSA: 205.84
ALOGS: -3.75
ROTB: 23

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	178.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.35 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.33 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.05 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 1, 1968	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	223.34	23.50	50	2121	5515	56284381
Laryngitis fungal	87.63	23.50	13	2158	134	56289762
Sickle cell anaemia with crisis	73.01	23.50	20	2151	5008	56284888
Mucormycosis	64.29	23.50	16	2155	2758	56287138
Bacterial sepsis	50.21	23.50	14	2157	3735	56286161
Iron overload	42.15	23.50	9	2162	789	56289107
Liver iron concentration increased	41.04	23.50	5	2166	8	56289888
Haemoglobin decreased	35.38	23.50	34	2137	134103	56155793
Haemosiderosis	33.69	23.50	6	2165	203	56289693
Blood creatinine increased	30.45	23.50	25	2146	80166	56209730
Infective chondritis	30.22	23.50	4	2167	16	56289880
Transplant failure	26.60	23.50	7	2164	1502	56288394
Maculopathy	24.49	23.50	7	2164	2037	56287859
Caesarean section	24.20	23.50	12	2159	16079	56273817
Injection site abscess	23.84	23.50	6	2165	1080	56288816

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	181.67	23.28	47	1975	5745	31689577
Blood iron increased	37.36	23.28	9	2013	815	31694507
Spinal X-ray abnormal	34.64	23.28	4	2018	0	31695322
Iron overload	33.92	23.28	9	2013	1202	31694120
Liver iron concentration increased	30.98	23.28	4	2018	6	31695316
Visual acuity reduced	29.74	23.28	16	2006	15327	31679995
Myelodysplastic syndrome	28.96	23.28	17	2005	19234	31676088
Blood creatinine increased	27.44	23.28	31	1991	89047	31606275

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serum ferritin increased	289.51	21.18	70	3227	8935	70916212
Fundoscopy abnormal	140.26	21.18	18	3279	41	70925106
Laryngitis fungal	78.26	21.18	12	3285	128	70925019
Mucormycosis	72.28	21.18	23	3274	7991	70917156
Spinal X-ray abnormal	52.21	21.18	7	3290	25	70925122
Sickle cell anaemia with crisis	49.17	21.18	16	3281	5962	70919185
Iron overload	48.71	21.18	12	3285	1641	70923506
Liver iron concentration increased	48.37	21.18	6	3291	9	70925138
Visual acuity reduced	47.39	21.18	24	3273	27906	70897241
Haemoglobin decreased	40.97	21.18	49	3248	205110	70720037
Myelodysplastic syndrome	37.55	21.18	21	3276	29764	70895383
Agranulocytosis	36.62	21.18	23	3274	40275	70884872
Maculopathy	34.20	21.18	10	3287	2616	70922531
Bacterial sepsis	34.17	21.18	13	3284	7634	70917513
Haemosiderosis	33.77	21.18	7	3290	440	70924707
Blood creatinine increased	31.59	21.18	36	3261	142965	70782182
Blood iron increased	30.32	21.18	8	3289	1436	70923711
Infective chondritis	27.23	21.18	4	3293	31	70925116
Haemochromatosis	26.28	21.18	7	3290	1304	70923843
Optic neuropathy	23.96	21.18	8	3289	3225	70921922
Retinopathy	23.32	21.18	8	3289	3498	70921649
Foetal distress syndrome	22.21	21.18	5	3292	463	70924684
Thalassaemia beta	21.56	21.18	3	3294	15	70925132

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AC01	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Iron chelating agents
FDA MoA	N0000000144	Iron Chelating Activity
FDA EPC	N0000175522	Iron Chelator
CHEBI has role	CHEBI:26672	siderochromes
CHEBI has role	CHEBI:38157	iron chelating agents
CHEBI has role	CHEBI:173084	ferroptosis inhibitors
MeSH PA	D002614	Chelating Agents
MeSH PA	D007502	Iron Chelating Agents
MeSH PA	D064449	Sequestering Agents
MeSH PA	D017262	Siderophores
CHEBI has role	CHEBI:50247	antidotes

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Poisoning by iron AND/OR its compounds	indication	55381001
Chronic Iron Overload	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.38	acidic
pKa2	8.99	acidic
pKa3	9.53	acidic
pKa4	13.04	acidic
pKa5	13.65	acidic
pKa6	10.56	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Hypoxia-inducible factor 1-alpha	Transcription factor	Q16665	HIF1A_HUMAN		EC50	4.75		CHEMBL
Deoxyhypusine hydroxylase	Enzyme	Q9BU89	DOHH_HUMAN		IC50	5.30		CHEMBL

External reference:

ID	Source
4019705	VUID
N0000147797	NUI
D01186	KEGG_DRUG
138-14-7	SECONDARY_CAS_RN
3131	RXNORM
4018789	VANDF
4019705	VANDF
C0011145	UMLSCUI
CHEBI:4356	CHEBI
CHEMBL556	ChEMBL_ID
CHEMBL1234	ChEMBL_ID
D003676	MESH_DESCRIPTOR_UI
DB00746	DRUGBANK_ID
1682	INN_ID
J06Y7MXW4D	UNII
2973	PUBCHEM_CID
4539	MMSL
46738	MMSL
d01402	MMSL
001089	NDDF
004540	NDDF
372825006	SNOMEDCT_US
387224002	SNOMEDCT_US
70702006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Desferal	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0467	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	NDA	31 sections
Desferal	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0467	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	NDA	31 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2336	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	19 sections
Deferoxamine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2337	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	19 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-623	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-623	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-624	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-624	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	52609-4504	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	52609-4505	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6236	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6237	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections
Deferoxamine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6238	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	12 sections
Deferoxamine	Human Prescription Drug Label	1	63323-597	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	95 mg	INTRAVENOUS	ANDA	17 sections
Deferoxamine	Human Prescription Drug Label	1	63323-599	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	95 mg	INTRAVENOUS	ANDA	17 sections
Deferoxamine mesylate	Human Prescription Drug Label	1	68083-172	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
Deferoxamine mesylate	Human Prescription Drug Label	1	68083-173	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections